Aki Hirayama

Prof. Dr. Aki Hirayama

Center for Integrative Medicine, Tsukuba University of Technology, Tsukuba, Japan

Research Focus & Metrics

Academic Career Length

57Years (1970-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2001 in Kidney International
Verified
Journal Article
Closed access
KYKeigyou Yoh
Keigyou Yoh
KIKen Itoh
Ken Itoh
AEAkiko Enomoto
Akiko Enomoto
Aki HirayamaAki Hirayama
Aki Hirayama
NYNaoto Yamaguchi
Naoto Yamaguchi
STSatoru Takahashi
Satoru Takahashi

21 October 2008 in Genes to Cells
Verified
Journal Article
Open access
PDF file
KYKeigyou Yoh
Keigyou Yoh
Aki HirayamaAki Hirayama
Aki Hirayama
KIKazusa Ishizaki
Kazusa Ishizaki
AYAkiko Yamada
Akiko Yamada
MTMasayoshi Takeuchi
Masayoshi Takeuchi
MYMasayuki Yamamoto
Masayuki Yamamoto
The transcription factor Nrf2 regulates the expression of antioxidant genes. Hyperglycemia‐induced oxidative stress is involved in the pathogenesis of diabetes and its complications. However, little is known about the protective role of Nrf2 in diabetes. To gain insight into the protective role of Nrf2 in diabetes we treated Nrf2 knockout (Nrf2 KO) mice with streptozotocin (STZ). The STZ Nrf2 KO mice did not develop renal hyperfiltration, which was observed in the STZ‐treated wild‐type (STZ WT) mice, but renal function gradually deteriorated over the 10‐week observation period. Urinary excretion of nitric oxide metabolites and the occurrence of 8‐nitroguanosine, which was detected in glomerular lesions, were increased in STZ Nrf2 KO mice during the early stages after treatment. In vivo electron paramagnetic resonance analysis revealed an accelerated rate of decay of the 3‐carbamoyl‐2,2,5,5‐tetramethylpyrrolidine‐1‐oxyl spin probe signal in STZ Nrf2 KO mice. The addition of superoxide dismutase prolonged the half‐life of the signal, which suggested that increased oxygen radical formation occurred in the STZ Nrf2 KO mice. These results suggested that hyperglycemia increased oxidative and nitrosative stress and accelerated renal injury in the Nrf2 KO mice and that Nrf2 serves as a defense factor against some diabetic complications.

1 April 1997 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
SNSohji Nagase
Sohji Nagase
KTKatsumi Takemura
Katsumi Takemura
AUAtsushi Ueda
Atsushi Ueda
Aki HirayamaAki Hirayama
Aki Hirayama
KAKazumasa Aoyagi
Kazumasa Aoyagi
AKAkio Koyama
Akio Koyama

1 November 2011 in Biomaterials
Verified
Journal Article
Open access
TYToru Yoshitomi
Toru Yoshitomi
Aki HirayamaAki Hirayama
Aki Hirayama
YNYukio Nagasaki
Yukio Nagasaki
The ultimate objective of nanoparticle-based therapy is to functionalize nanomedicines in a micro-disease environment without any side effects. Here, we reveal that our pH-responsive nitroxide radical-containing nanoparticles (RNP(pH)) disintegrate within the renal acidic lesion and act as scavengers of reactive oxygen species (ROS), leading to a relief of acute kidney injury (AKI). RNP(pH) was prepared using amphiphilic block copolymers possessing 2,2,6,6-tetramethylpiperidine-N-oxyl (TEMPO) moieties via amine linkage as a side chain of the hydrophobic segment. The self-assembled RNP(pH) disintegrated at pH below 7.0 because of a protonation of the amino groups in the hydrophobic core of the nanoparticles, thereby resulting in an improvement in ROS scavenging activity. Using a renal ischemia-reperfusion AKI model in mice, the therapeutic effect of RNP(pH) on ROS damage was evaluated. Unlike the RNP without pH-triggered disintegration (RNP(Non-pH)), the RNP(pH) showed extremely high ROS scavenging activity and renal protective effects. It is interesting to note that the side effect of nitroxide radicals was markedly suppressed due to the compartmentalization of nitroxide radicals in the core of RNP(pH) in untargeted area. The morphology changes in RNP(pH) were confirmed by analyzing electron spin resonance spectra, and these findings provide the evidence of the real therapeutic effect of the environment-sensitive specific disintegration of nanoparticles in vivo.

18 December 2003 in Oncogene
Verified
Journal Article
Closed access
NMNaoki Morito
Naoki Morito
KYKeigyou Yoh
Keigyou Yoh
KIKen Itoh
Ken Itoh
Aki HirayamaAki Hirayama
Aki Hirayama
AKAkio Koyama
Akio Koyama
Satoru TakahashiSatoru Takahashi
Satoru Takahashi

1 May 2009 in Cancer Letters
Verified
Journal Article
Closed access
AOAki Ogura
Aki Ogura
SOShigeru Oowada
Shigeru Oowada
YKYasuhiro Kon
Yasuhiro Kon
Aki HirayamaAki Hirayama
Aki Hirayama
HYHironobu Yasui
Hironobu Yasui
OIOsamu Inanami
Osamu Inanami